ACE-031 vs Follistatin: What’s the Difference?
The main difference between ACE-031 and Follistatin is mechanism: ACE-031 is studied for myostatin pathway inhibition research — Binds circulating myostatin, activin A, and related TGF-β ligands before they can activate ActRIIB on muscle cells. Follistatin is studied for myostatin inhibition research — Powerful glycoprotein.
Activin receptor decoy vs myostatin-binding protein.
Key differences between ACE-031 and Follistatin
- •Mechanism: ACE-031 — Binds circulating myostatin, activin A, and related TGF-β ligands before they can activate ActRIIB on muscle cells. Follistatin — Powerful glycoprotein.
- •Primary research focus: ACE-031 is studied for myostatin pathway inhibition research; Follistatin is studied for myostatin inhibition research.
- •Overlap: the two compounds share muscle growth & performance.
- •Discussion context: ACE-031 is most often discussed alongside myostatin pathway inhibition research, while Follistatin centres on myostatin inhibition research.
| Attribute | ACE-031 Activin receptor type IIB (soluble) | Follistatin FST-344 |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Best known for | Myostatin pathway inhibition research | Myostatin inhibition research |
| Mechanism of action | Binds circulating myostatin, activin A, and related TGF-β ligands before they can activate ActRIIB on muscle cells. | Powerful glycoprotein. Temporarily blocks myostatin — the body's genetic 'brake' on muscle growth. |
| Human research | Not catalogued | Limited |
| Animal research | Not catalogued | Moderate |
| Mechanistic research | Not catalogued | Emerging |
| Study cadence cited | — | Daily during 10-day cycle |
| In plain English | It acts like a sponge that soaks up the signals telling your body to stop building muscle. | Myostatin is the brake on muscle growth. Follistatin is researched as the brake-release mechanism. |
| How it works | Binds circulating myostatin, activin A, and related TGF-β ligands before they can activate ActRIIB on muscle cells. | Binds and neutralizes myostatin, activin, and related TGF-β family members that limit muscle growth. |
| Researchers study | Muscular dystrophy, sarcopenia, and lean-mass research models. | Muscle hypertrophy, muscular dystrophy, and aging-related sarcopenia. |
| Internet discussion | Discussed alongside follistatin and YK-11 in muscle-growth research circles. | Hyped in bodybuilding research circles. |
Mechanism and research evidence, side by side
How ACE-031 and Follistatin differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Follistatin
Powerful glycoprotein. Temporarily blocks myostatin — the body's genetic 'brake' on muscle growth.
- IGF-1 / myostatin-axis receptors
- Satellite-cell activation and protein-synthesis signalling
- Hypertrophy and tissue-remodelling endpoints
- Human research
- Limited
- Animal research
- Moderate
- Mechanistic research
- Emerging
Temporarily bypass myostatin to push past genetic muscle limits
ACE-031
Myostatin pathway inhibition research
It acts like a sponge that soaks up the signals telling your body to stop building muscle.
Binds circulating myostatin, activin A, and related TGF-β ligands before they can activate ActRIIB on muscle cells.
Muscular dystrophy, sarcopenia, and lean-mass research models.
Discussed alongside follistatin and YK-11 in muscle-growth research circles.
ACE-031 is a soluble ActRIIB decoy researched as a myostatin/activin trap to support muscle growth.
Follistatin
Myostatin inhibition research
Myostatin is the brake on muscle growth. Follistatin is researched as the brake-release mechanism.
Binds and neutralizes myostatin, activin, and related TGF-β family members that limit muscle growth.
Muscle hypertrophy, muscular dystrophy, and aging-related sarcopenia.
Hyped in bodybuilding research circles.
Follistatin is a glycoprotein researched for myostatin inhibition and muscle hypertrophy.